Tag Archives: Spinal cord injury

Spinal Cord Injury

Stem Cell Research Clinical Study- Spinal Cord Injury
A few weeks ago, I covered a story about  a stem cell research published study for spinal cord injury patients in Ecuador.  In that study, Dr. Luis Geffner used 3 different delivery methods of Adult Stem Cells to help 52 spinal cord injury patients and counting.
Michael Flounders- Walking […]

First Spinal-Cord Surgery With Stem Cells

Dr. Donald Leslie, medical director at the Shepherd Center in Atlanta, has high hopes.

“We want to cure paralysis,” he said. “We want to stop spinal cord injury. How incredible would that be?”

Leslie’s mission has begun with T.J. Atchinson, the first step in research that he believes could lead to many steps for those who were told they would never walk again. Atchinson, 21, was the first human with a spinal cord injury to undergo embryonic stem cell therapy.

The athletic college student’s life took a hard turn in September when he was home from the University of Alabama visiting his
Read More…

Stem Cell Company Presents Findings Of Adult Stem Cell Safety And Feasibility Study

DaVinci Biosciences LLC, of Costa Mesa, CA, announced today the presentation of their safety and feasibility study demonstrating the administration of autologous bone marrow derived stem cells for the treatment of acute and chronic spinal cord injury at Neuroscience 2009, Society for Neuroscience’s 39th Annual Meeting, to be held at McCormick Convention Center in Chicago, IL. Rafael Gonzalez, Ph.D., Director of Research and Development for DaVinci Biosciences LLC will present the work during the conference on October 20, 2009 and be available to answer questions regarding the study, following his presentation.

“We are excited to share the findings
Read More…

StemCells Inc Announces Closing of $20 MLN Offering

StemCells Inc announced that it has closed its previously announced offering of common stock and short term warrants. The Company sold a total of 11,299,435 units to two well recognized institutional biotechnology investors and received total proceeds, net of offering expenses and placement agent fees, of approximately $18.7 million.

Each unit consists of one share of common stock and a warrant to purchase 0.85 of a share of common stock at a price of $1.77 per unit. The warrants will first be exercisable six months from the date of issuance at an initial exercise price of $2.17 per share. The
Read More…

Graphene & electricity to change stem cells for nerve regrowth

Researchers looking for ways to regenerate nerves can have a hard time obtaining key tools of their trade.

Schwann cells are an example. They form sheaths around axons, the tail-like parts of nerve cells that carry electrical impulses. They promote regeneration of those axons. And they secrete substances that promote the health of nerve cells.

In other words, they’re very useful to researchers hoping to regenerate nerve cells, specifically peripheral nerve cells, those cells outside the brain and spinal cord.

But Schwann cells are hard to come by in useful numbers.

So researchers have been taking readily available and noncontroversial mesenchymal stem cells
Read More…